drugset / Trial / NCT07503002

Shortened LSD Intervention for Major Depressive Disorder

NCT07503002

Phase 1 Not yet recruiting 10 enrolled Johns Hopkins University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.

Timeline

Start
2026-07-01
Primary completion
2027-07-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lysergic Acid Diethylamide Other / unclassified 250 ug Oral
Subject Risperidone Other / unclassified 1 mg Oral